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A classic legend immortalized by Goethe in 1808 tells of
humanity’s quest for the true essence of life. Through the
allegory of Mephistopheles, Faust reaches for the supernat-
ural to overcome his human limitations. Stem cell research
has in a way brought us in touch with near supernatural
powers as we begin to understand and explore the mecha-
nisms imbuing these cells with the capacity for self-renewal.
The question of aging is central to stem cell biology, and the
harnessing of these powers, even in part, may change the
way we deal with aging and disease.
See page 2237
Delivery of stem cells to the heart directly or via the use
of a tissue-engineered platform is a clinically promising
approach to improve clinical outcomes by enhancing the
healing process after myocardial infarction (MI) or by
facilitating functional gain in the setting of chronic ischemic
heart disease. However, when considering autologous cell
therapy, the benefits of this approach may be limited in one
of the largest target groups for regenerative medicine—the
elderly—because of age-related dysfunction in stem cells.
Moreover, the use of autologous stem cells in patients with
chronic heart disease is further hampered by the comorbidi-
ties common in this patient group, which also have a
negative effect on the potency of bone marrow–derived stem
cells (1,2).
Dysfunction of stem cells harvested from the bone mar-
row of aged patients has been clearly demonstrated (3) and
verified in cell therapy trials of autologous bone marrow cells
in patients with heart failure (4). In the FOCUS-HF (First
Bone Marrow Mononuclear Cell United States Study in
Heart Failure) trial, we showed that the regenerative capac-
ity of the mesenchymal compartment of bone marrow cells
was greater in younger patients than in older patients, and
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clinical outcomes (4). In the largest study of cell therapy
with autologous bone marrow cells in patients with chronic
heart failure (5), better functional outcomes also were
identified in younger patients and were associated with the
presence of specific cell phenotypes.
In this issue of the Journal, Kang et al. (6) address the
issue of function of aged cells in a rat model of surgical
ventricular restoration after MI. They seeded human mes-
enchymal stromal cells (MSCs) onto collagen scaffolds and
showed, not surprisingly, that MSCs from older donors
proliferated in vitro on the scaffolds more slowly than did
MSCs from younger donors. However, binding angiogenic
cytokines to the scaffolds enabled the older MSCs to
overcome this proliferation deficit. Of note, Kang et al. (6)
showed that the salutary effects of cytokine exposure on
older cells extended to the in vivo environment. After
surgical ventricular restoration in rats with MI, the limited
functional and vascular benefits of cardiac patches seeded
with old cells improved, often to the level noted with
patches that carried young cells, with the use of cytokine-
enhanced patches (1).
Age-related changes in stem cells are the Achilles’ heel of
autologous cell therapy. We propose 4 different, sometimes
overlapping, strategies for overcoming this problem. First,
the most obvious way is to not use autologous cells in cell
therapy. The initial clinical experience with the use of
allogeneic bone marrow–derived mesenchymal stem cells in
patients with MI (7) showed that the therapy was well
tolerated and that immunosuppression was not required; the
action of the mesenchymal cells may be in part immuno-
modulatory. In addition, we have shown that allogeneic
mesenchymal precursor cells improved clinical outcomes
and functional benefits in patients with heart failure (8).
This approach, although promising, will require confirma-
tion in larger studies.
Second, using stem cells from other tissue sources may
circumvent the problem of age-related decline in potency
seen in bone marrow cells. Adipose tissue seems to be a
promising source of stem cells. In a preliminary study in
patients with ischemic cardiomyopathy, we have shown that
the transendocardial injection of adipose-derived regenera-
tive cells was safe and feasible, with encouraging efficacy
data (9). The resiliency of adipose tissue is evidenced by
patients’ ability to gain weight easily even in the presence of
multiple comorbidities known to inhibit stem cell function.
It may be that certain tissues are less exposed to the
detrimental effects of disease and aging.
Third, we may be able to turn back the clock on
senescent, dysfunctional stem cells by treating them with
genetic factors before delivery to reverse or forestall the
aging process. Experimental in vitro data suggest that the 2
nuclear proteins myocardin A and telomerase reverse tran-
scriptase may interact to maintain the stem cell–like features
of mesenchymal stem cells derived from adipose tissue (10).
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whereas myocardin A promotes expression of promyogenic
genes. Hypothetically then, increasing the expression of
these 2 factors in aging mesenchymal cells may potentially
enhance their myogenic regenerative properties contributing
to their growth and differentiation into cardiovascular myo-
cytes. Another significant molecular player in the aging
process is the mammalian target of rapamycin pathway,
which regulates cell growth and proliferation. Of note, the
paradigm of glucose homeostasis seems to be linked to
lifespan prolongation through the inhibition of mammalian
target of rapamycin complex 1, which may provide protec-
tion from age-related diseases (11,12). Unraveling the
molecular aspects of cellular aging is densely complex, and
multiple genetic targets may emerge as applicable to clinical
therapies.
Last, and most pertinent to the study of Kang et al. (6),
is rejuvenation of the target tissue. Age-related changes in
the tissue environment, or the stem cell niche, may affect the
regenerative capacity of delivered stem cells and resident
stem cells (3). Much research has focused on aging mech-
anisms within the cell, but providing a more youthful tissue
environment for delivery of cells may improve the functional
benefits associated with cell therapy, even in older patients.
The effects of youthful rejuvenation of aged tissues have
been studied in the setting of heterochronic parabiosis, in
which 2 age-mismatched animals (old and young) are
surgically connected via a large flap of skin, thereby joining
circulatory systems and exposing the tissue of old animals to
a younger systemic milieu. By using this ingenious ap-
proach, investigators have shown that exposure to a rejuve-
nated environment improves regenerative responses of aged
cells to liver, muscle, and brain injuries (13,14).
The present study by Kang et al. (6) provides us with a
platform on which to begin building a construct for making
aged cells more effective in autologous therapy. Science is
poised to make a great leap in the understanding of the
mechanisms of senescence and regeneration and in applying
that knowledge for advancing cellular therapies. This jour-
ney into discovery of the aging process at the cellular level
may be one of the greatest endeavors of modern-day science.
Much as Faust finds redemption from his transcendental
quest, humankind, through more rational means, stands to
find fundamental and rewarding answers from our observa-
tions of nature.Reprint requests and correspondence: Dr. Emerson C. Perin,
Texas Heart Institute, 6624 Fannin, Suite 2220, Houston, Texas
77030. E-mail: eperin@bluegate.com.
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